MorphoSys Expands Collaboration With Centocor
Under the extended agreement, Centocor has the option to elect up to 30 disease-related target molecules, against which the two parties will develop fully human, optimized antibodies using the HuCAL GOLD® technology of MorphoSys. MorphoSys stands to receive licensing and milestone payments, in addition to royalties on any marketed antibody products arising from the collaboration. Furthermore, Centocor maintains access to HuCAL GOLD® to isolate antibodies for research use. In the collaboration with Centocor, MorphoSys has achieved four performance-related milestones to date. In March 2004, both companies launched a new antibody program to develop a therapeutic antibody against a Centocor target molecule involved in autoimmune diseases.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous